source
- J&J returns rights to lymphoma CAR‑T therapy prizlon‑cel to AbelZetaJohnson & Johnson secured exclusive rights to the bispecific CAR T candidate prizlon‑cel in 2023, paying an upfront $245 million. The therapy, designed for large B‑cell lymphoma, achieved a 100% r…
- North Carolina’s bipartisan Medicaid pilot shows social services can cut health costsThe article, written by former state health secretaries Mandy Cohen and Kody Kinsley, says North Carolina’s health‑care affordability crisis was tackled through a bipartisan pilot. The Healthy Opp…